Compare Axogen Inc (AXGN) vs Crocs, Inc. (CROX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Crocs, Inc. — how do they compare? Axogen Inc trades at $48.85 (market cap $2.59B), while Crocs, Inc. trades at $131.6 (market cap $6.63B). The key difference: Crocs, Inc. is far larger — about 2.6× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals.
| AXGN | CROX | |
|---|---|---|
Market Cap | $2.59B | $6.63B |
Sector | Technology | Consumer Staples |
52-Week High | $48.22 | $141.19 |
52-Week Low | $14.01 | $73.39 |
Enterprise Value | $2.50B | $8.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
